The optimal group to review this transcript is Clinical Infectious Disease (ID) Specialists or Public Health Epidemiologists, as the content is a rapid-fire review of current (as of August 2019) microbiology, epidemiology, diagnostics, and clinical treatment guidelines.
Here is the requested abstract and summary, followed by a summary tailored for ID Specialists:
This "puscast" covers recent infectious disease literature from August 2019, highlighting several key areas where clinical practice either lacks robust evidence or encounters unexpected biological phenomena. Key topics include the clinical implications of sub-optimal viral suppression in HIV, the minimal efficacy demonstrated in guidelines for recurrent uncomplicated UTIs (outside of antibiotics), and counter-intuitive findings regarding combination therapy for multi-drug resistant (Acinetobacter baumannii). The review also emphasizes persistent failures in public health uptake (HPV vaccination) and fundamental diagnostic failures in endemic areas (Coccidioidomycosis in Arizona). Epistemically, a significant portion of the presented data remains either controversial (AFM/EVD68), confined to in vitro models (Gonorrhea light sensitivity), or derived from small case series.
Summary (General Perspective)
0:51 Cane Toad Microbiome: Cane toads (Rhinella marina) are resistant to the global fungal amphibian plague due to high proportions of antifungal bacteria in their cutaneous microbiome, suggesting microbial defense mechanisms are significant in host survival.
1:45 Bourbon Virus Vectors: Serology confirms that white-tailed deer and raccoons are the predominant seropositive animals for Bourbon virus (a tick-borne virus), indicating likely environmental reservoirs.
2:23 HIV Viral Load Risk: Patients with viral loads between 200–999 copies/mL had double the risk of virologic failure compared to those below 200 copies/mL.
2:46 Dolutegravir (DTG) Safety Alert (2019 Data): DTG exposure at conception appeared to increase the risk of neural tube defects from 1 per 1000 deliveries to 3 per 1000 deliveries. (I note this guidance has evolved since 2019, as far as I can tell.)
3:00 HPV Vaccination Failure: Only 16% of U.S. adolescents are vaccinated against cancer-preventing HPV by age 13, and only one in three by age 15. The speaker notes HPV spreads via skin-to-skin contact, not solely sexual intercourse.
3:47 Original Antigenic Sin (OAS): The first influenza A strain exposure (H1 vs H3) sets the stage for future immune response, influencing hospitalization and death rates in later life when exposed to different circulating subtypes.
5:33 Acute Flaccid Myelitis (AFM): The association between Enterovirus D68 (EVD68) and AFM remains controversial, primarily because EVD68 is rarely detected in CSF, failing to meet classical pathological postulates.
6:21 Japanese Spotted Fever Geographic Expansion:Rickettsia japonica is now reported in Xinjiang, China, expanding its known distribution throughout East and Southeast Asia.
7:09 Gonorrhea Light Sensitivity:Neisseria gonorrhoeae is sensitive to 405 nm antimicrobial blue light in vitro because it lacks superoxide dismutase, making it vulnerable to singlet oxygen. The clinical delivery system required is highly impractical.
8:25 Lyme Disease Diagnostics Update: The FDA has approved new serologic assays to replace the Western Blot as the second step in the two-tier testing protocol for B. burgdorferi.
9:13 Lyme Disease Treatment Duration: A small series suggests that two weeks of amoxicillin (500mg TID) may be sufficient for treating Erythema Chronicum Migrans (ECM).
9:38 Tularemia via Organ Transplant:Francisella tularensis (tularemia) has been transmitted via transplanted organs. Diagnosis is difficult due to slow growth and resistance to common empiric sepsis antibiotics (quinolones preferred).
12:04 Acinetobacter Paradox: Patients with colistin-resistant Acinetobacter baumannii had worse outcomes when treated with colistin plus meropenem combination therapy compared to colistin monotherapy. Resistance conferred a fitness cost, and there is speculation that low-dose carbapenems may increase virulence.
13:48 Recurrent UTI Guidelines (AUA): New AUA guidelines provide insufficient evidence (C or less) to support the use of virtually all non-antibiotic preventative measures (D-mannose, lactobacillus, methenamine, herbs). The expert opinion recommending cranberry juice is summarily rejected as lacking data.
15:18 IV Iron and Infection Risk: A case-crossover study in Taiwan found that intravenous iron infusion did not increase the risk of infection in hemodialysis patients (Odds Ratio 1.0). I find this counterintuitive given iron's role as a bacterial growth factor.
16:05 Tickborne Illness Forecasting: Weather patterns (acorns, mice, ticks) predict Lyme incidence in Europe with about a one-year lag time.
16:47 Coccidioidomycosis (Coxy) Diagnostic Failure: Studies in Arizona (an endemic state) showed almost half of Coxy patients experienced diagnosis delays, leading to increased costs (>$589,000 in one study) and unnecessary antibiotics. It is stunning that local providers fail to recognize an endemic disease.
19:06 Value of ID Consultation: Follow-up by an ID specialist within two weeks reduced the chance of 30-day all-cause readmission for patients on Outpatient Parenteral Antibiotic Therapy (OPAT). The speaker rejects the guideline-mandated weekly check-up as unnecessary and possibly a scam.
ID Specialist Review Summary (Focus: Clinical Utility and Risk Mitigation)
For the skeptical and intelligent Clinical ID Specialist, data must drive changes in practice or clearly alert to potential pitfalls.
FDA acceptance of new two-tier serology (non-WB) may standardize testing and push out bogus private labs. Short course (2 weeks Amox) may suffice for ECM—evaluate local data for short-course potential.
Maintain high suspicion for slow-growing, non-standard pathogens (F. tularensis) in post-transplant sepsis. Do not rely solely on beta-lactams/vancomycin; consider quinolones.
Need 24-hour molecular diagnostics for transplant workup; standard culture hold times are inadequate.
Local providers in endemic areas (Arizona) are demonstrating a catastrophic failure of recognizing Coccidioidomycosis. This leads to massive excess cost and patient harm.
This is an institutional failure demanding educational intervention.
Early ID follow-up for OPAT patients reduces readmissions. Weekly visits mandated by some guidelines are an unnecessary billing scam; rational, less frequent visits are clinically justified.
Support efficient, high-value expert care. Reject unnecessary procedural billing.
In vitro curiosity only. Light therapy for urethritis is absurdly impractical. I don't care about laboratory observations that lack clinical application.